Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Journal of Neuro-Oncology|February 24, 2021
Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patientsAnne-Sophie Montero, Suzanne Tran, Aymeric Amelot, et al.
Neurology|September 30, 2022
In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of <i>IDH</i>-Mutant Diffuse Gliomas: The <i>IDASPE</i> Prospective StudyAnna Luisa Di Stefano, Lucia Nichelli, Giulia Berzero, et al.
Acta Neuropathologica Communications|November 10, 2020
Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosisHélène Lasolle, Mad-Hélénie Elsensohn, Anne Wierinckx, et al.
European Journal of Endocrinology|February 8, 2024
KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomasFanny Chasseloup, Daniela Regazzo, Lucie Tosca, et al.
The Journal of Clinical Endocrinology and Metabolism|July 28, 2010
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experienceGérald Raverot, Nathalie Sturm, Florence de Fraipont, et al.
Endocrine-Related Cancer|May 24, 2017
Loss-of-function mutations in the <i>CABLES1</i> gene are a novel cause of Cushing's diseaseLaura C Hernández-Ramírez, Ryhem Gam, Nuria Valdés, et al.
The Journal of Clinical Endocrinology and Metabolism|October 27, 2020
Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX MutationsOlivera Casar-Borota, Henning Bünsow Boldt, Britt Edén Engström, et al.
Medrxiv : the Preprint Server for Health Sciences|January 30, 2023
Germline loss-of-function <i>PAM</i> variants are enriched in subjects with pituitary hypersecretionGiampaolo Trivellin, Adrian F Daly, Laura C Hernández-Ramírez, et al.
Frontiers in Endocrinology|June 30, 2023
Germline loss-of-function <i>PAM</i> variants are enriched in subjects with pituitary hypersecretionGiampaolo Trivellin, Adrian F Daly, Laura C Hernández-Ramírez, et al.
European Journal of Endocrinology|April 23, 2017
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomasHélène Lasolle, Christine Cortet, Fréderic Castinetti, et al.
Pageof 9